MX2017007607A - Inhibidores de necrosis celular y metodos relacionados. - Google Patents

Inhibidores de necrosis celular y metodos relacionados.

Info

Publication number
MX2017007607A
MX2017007607A MX2017007607A MX2017007607A MX2017007607A MX 2017007607 A MX2017007607 A MX 2017007607A MX 2017007607 A MX2017007607 A MX 2017007607A MX 2017007607 A MX2017007607 A MX 2017007607A MX 2017007607 A MX2017007607 A MX 2017007607A
Authority
MX
Mexico
Prior art keywords
inhibitors
related methods
cellular necrosis
treatment
compounds
Prior art date
Application number
MX2017007607A
Other languages
English (en)
Spanish (es)
Inventor
Yuan Junying
Zhou Yijun
qian Shan
Ma Dawei
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX2017007607A publication Critical patent/MX2017007607A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2017007607A 2014-12-11 2015-12-11 Inhibidores de necrosis celular y metodos relacionados. MX2017007607A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410767595 2014-12-11
CN201410764426 2014-12-11
US201562105462P 2015-01-20 2015-01-20
US201562105475P 2015-01-20 2015-01-20
PCT/US2015/065349 WO2016094846A1 (en) 2014-12-11 2015-12-11 Inhibitors of cellular necrosis and related methods

Publications (1)

Publication Number Publication Date
MX2017007607A true MX2017007607A (es) 2018-05-28

Family

ID=56108283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007607A MX2017007607A (es) 2014-12-11 2015-12-11 Inhibidores de necrosis celular y metodos relacionados.

Country Status (14)

Country Link
US (3) US9944628B2 (show.php)
EP (1) EP3229807A4 (show.php)
JP (1) JP2017538712A (show.php)
KR (1) KR20170123607A (show.php)
CN (1) CN107530350A (show.php)
AR (1) AR102981A1 (show.php)
AU (1) AU2015360291A1 (show.php)
CA (1) CA2970525A1 (show.php)
EA (1) EA201791289A1 (show.php)
IL (1) IL252827A0 (show.php)
MX (1) MX2017007607A (show.php)
SG (1) SG11201704764PA (show.php)
TW (1) TW201632516A (show.php)
WO (1) WO2016094846A1 (show.php)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122889A1 (en) 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US9643977B2 (en) 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
EA201791289A1 (ru) 2014-12-11 2017-12-29 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы клеточного некроза и связанные с ними способы
CN106619619A (zh) * 2017-01-06 2017-05-10 浙江大学 化合物hubin‑1在制备肝脏炎症性疾病预防和/或治疗药物中的用途
CN110573504A (zh) 2017-02-27 2019-12-13 葛兰素史克知识产权开发有限公司 作为激酶抑制剂的杂环酰胺
CA3063938A1 (en) 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods
CN108191835A (zh) * 2018-01-09 2018-06-22 中国药科大学 一类新型的含吡咯环和吲哚啉结构rip1激酶抑制剂及其用途
CN110759895B (zh) * 2018-07-25 2020-10-27 浙江大学 新型rip1/rip3双靶点抑制剂及其在一药多靶疾病治疗中的用途
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
US20210147842A1 (en) * 2019-11-13 2021-05-20 President And Fellows Of Harvard College Methods and compositions for inhibiting necroptosis in neurovascular and/or neurodegenerative diseases or disorders
CN112263576A (zh) * 2020-09-30 2021-01-26 浙江大学 化合物zju-37在制备肝脏疾病预防和/或治疗药物中的应用

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1044508A (en) * 1911-04-21 1912-11-19 Ajax Forge Company Railway-frog.
BE789948A (fr) 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
JPS5113156B2 (show.php) 1972-10-21 1976-04-26
US4016037A (en) 1975-10-15 1977-04-05 Ajinomoto Co., Inc. Method for producing L-amino acid
US4110536A (en) 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
DE2728523C2 (de) 1977-06-23 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 4-Methyl-1,2,3-thiadiazol-5-carbonsäure-(cyclohexylmethyl)-amid, Mittel mit herbizider und wachstumsregulatorischer Wirkung enthaltend diese Verbindung sowie Verfahren zu seiner Herstellung
JPS55136279A (en) * 1979-04-09 1980-10-23 Ajinomoto Co Inc Preparation of tryptophan hydantoin
JPS5810074B2 (ja) 1979-07-18 1983-02-24 味の素株式会社 新規微生物
GB2080803B (en) 1980-07-28 1984-01-18 Pfizer Hypoglycemic 5-substituted oxazolidine-2,4-diones
US4332952A (en) 1980-07-28 1982-06-01 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
EP0164247B1 (en) 1984-06-07 1989-01-11 Pfizer Limited Dihydropyridines
JPS6122081A (ja) 1984-07-10 1986-01-30 Mitsui Toatsu Chem Inc ヒダントイン化合物の製造法
US4684735A (en) 1985-07-01 1987-08-04 Stauffer Chemical Company Promotion of raney nickel hydrogenation catalyst
JPH0623148B2 (ja) 1985-09-05 1994-03-30 三井東圧化学株式会社 Ｎ−アセチル−ｄｌ−アミノ酸の製造方法
CA1292840C (en) 1985-09-26 1991-12-03 David Harry Hawke Sequencing of peptides
JPH0659227B2 (ja) 1985-11-08 1994-08-10 三井東圧化学株式会社 Ｄ−α−アミノ酸の製造方法
JPS6225990A (ja) 1986-07-19 1987-02-03 Kanegafuchi Chem Ind Co Ltd Ｄ−α−アミノ酸類の製造方法
US4705864A (en) 1986-11-10 1987-11-10 The Standard Oil Company Aryl oxime derivatives of hydantoins
US4911931A (en) 1987-08-03 1990-03-27 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
JP2661111B2 (ja) 1988-03-09 1997-10-08 三菱化学株式会社 Ｄ−Ｎ−カルバミル−α−アミノ酸の製造法
US4868061A (en) 1988-05-19 1989-09-19 The Standard Oil Company Olefinic aryl oxime derivatives of hydantoins
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
WO1990004183A1 (en) 1988-10-07 1990-04-19 Commonwealth Scientific And Industrial Research Organisation Method for preparation of thiohydantoins and for protein sequence analysis
ATE94906T1 (de) 1989-01-02 1993-10-15 Ruetgerswerke Ag Verfahren zur herstellung von l-alphaaminos|uren.
JPH054910A (ja) 1990-07-31 1993-01-14 Nikka Chem Co Ltd 化粧料組成物
JPH06502627A (ja) 1990-08-31 1994-03-24 ワーナー―ランバート・コンパニー 新規コレシストキニンアンタゴニスト、その製造および治療用使用
JP2651755B2 (ja) 1991-03-01 1997-09-10 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
DE69223573D1 (de) 1991-09-16 1998-01-29 Merck & Co Inc Hydantoin und Succinimid-substituierte Spiroindanylcamphorsulfonyl als Oxytocin-Antagonisten
US5693643A (en) 1991-09-16 1997-12-02 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
JP3163361B2 (ja) 1992-03-12 2001-05-08 味の素株式会社 ５−アルキルヒダントイン誘導体の製造法
DE69320730T2 (de) 1992-07-14 1999-02-11 Nippon Chemiphar Co. Ltd., Tokio/Tokyo Alkylendiaminderivate
US5574030A (en) 1992-07-14 1996-11-12 Nippon Chemiphar Co., Ltd. N-aminoalkyl-substituted nitrogen-containing five membered heterocyclic compounds
US5830854A (en) 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5338859A (en) 1993-02-12 1994-08-16 Hoechst Celanese Corporation Process for the production of calcium salts of hydantoic acids
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
AU701863B2 (en) 1994-09-08 1999-02-04 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1996030393A1 (en) 1995-03-27 1996-10-03 Warner-Lambert Company A method for the synthesis of mixtures of compounds
US6166054A (en) 1995-03-31 2000-12-26 Nihon Nohyaku Co., Ltd. Agricultural and horticultural disease controller and a method for controlling the diseases
US5674734A (en) 1995-05-18 1997-10-07 President And Fellows Of Harvard College Cell death protein
DE19519717C1 (de) 1995-05-30 1996-08-22 Degussa Neuer Mikroorganismus, dessen Verwendung und Verfahren zur Herstellung von L-alpha-Aminosäuren
US6846839B1 (en) 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US5962478A (en) 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
WO1997015586A1 (en) 1995-10-23 1997-05-01 Tularik, Inc. Rip: novel human protein involved in tumor necrosis factor signal transduction, and screening assays
EP0907643B1 (en) 1996-04-24 2003-01-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998014437A1 (en) 1996-09-30 1998-04-09 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives and salts thereof, disease controlling agents for agricultural and horticultural use, and method for the use thereof
US5859190A (en) 1997-02-04 1999-01-12 Trega Biosciences, Inc. Combinatorial libraries of hydantoin and thiohydantoin derivatives, methods of making the libraries and compounds therein
JP2001513821A (ja) 1997-03-03 2001-09-04 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 炎症性疾患の治療に有用な小分子
IL126024A0 (en) 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
EP0976326B1 (en) 1998-07-30 2003-05-02 Nihon Nohyaku Co., Ltd. Fungicidal composition containing a 1,2,3-tiadiazole derivative and its use
DE19940211A1 (de) 1998-09-22 2000-03-23 Degussa Verfahren zur Herstellung von Imidazolidin-2,4-dionen
US6020198A (en) 1998-09-25 2000-02-01 Isis Pharmaceuticals Inc. Antisense modulation of RIP-1 expression
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
WO2001007048A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6353013B1 (en) 1999-07-21 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001028493A2 (en) 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis
US6756394B1 (en) 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
US6706766B2 (en) 1999-12-13 2004-03-16 President And Fellows Of Harvard College Small molecules used to increase cell death
EP1275646A4 (en) 2000-03-30 2003-05-28 Sagami Chem Res INDOLYLPYRROL DERIVATIVES AND CELL DEATH INHIBITORS
US20020155172A1 (en) 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
GB0011071D0 (en) 2000-05-08 2000-06-28 Novartis Ag Organic compounds
US6846643B2 (en) 2000-08-14 2005-01-25 Boehringer Ingelheim Pharmaceuticals, Inc. Methods and molecules useful for identifying molecules that bind LFA-1 and for determining receptor occupancy
US20020064736A1 (en) 2000-09-27 2002-05-30 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and method for producing an azomethine dye
JP2002145192A (ja) 2000-11-07 2002-05-22 Yamaha Motor Co Ltd 水上乗物の燃料タンク構造
JP4529338B2 (ja) 2001-03-08 2010-08-25 味の素株式会社 ヒダントイナーゼをコードするｄｎａ、ｎ−カルバミル−ｌ−アミノ酸ハイドロラーゼをコードするｄｎａ、組み換えｄｎａ、形質転換された細胞、タンパク質の製造方法および光学活性アミノ酸の製造方法
WO2003027081A2 (en) 2001-09-14 2003-04-03 Novo Nordisk A/S NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
AU2002363655A1 (en) 2001-11-14 2003-05-26 Novartis Ag Non-peptide somatostatin receptor ligands
KR20050044581A (ko) 2001-11-22 2005-05-12 오노 야꾸힝 고교 가부시키가이샤 피페리딘-2-온 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
JP3659224B2 (ja) 2001-12-26 2005-06-15 村田機械株式会社 インターネットファクシミリ装置
US7189856B2 (en) 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
AU2003215077A1 (en) 2002-02-11 2003-09-04 Wyeth Solution structure of rip dd and uses therof
US20060099645A1 (en) 2002-09-06 2006-05-11 Mount Sinai Hospital Methods and reagents for assaying molecular interactions
MXPA05005653A (es) 2002-11-27 2005-11-23 Artesian Therapeutics Inc Determinacion y seleccion terapeutica de genes de insuficiencia cardiaca.
EP1585541B1 (en) 2002-12-20 2007-11-14 Novo Nordisk A/S Pharmaceutical compositions comprising insulin and legends of insulin hexamer
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0302671D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7320986B2 (en) 2003-03-07 2008-01-22 Abbott Labortories Fused tri and tetra-cyclic pyrazole kinase inhibitors
MXPA05009565A (es) 2003-03-11 2005-12-02 Novo Nordisk As Preparaciones farmaceuticas que comprenden insulina estabilizada con acido.
WO2004080481A1 (en) 2003-03-13 2004-09-23 Novo Nordisk A/S Novel nph insulin preparations
US7491743B2 (en) 2003-08-29 2009-02-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
DE10342839A1 (de) 2003-09-17 2005-04-28 Symrise Gmbh & Co Kg Thiohydantoine zur Aufhellung von Haut oder Haar
US20080019909A1 (en) 2003-09-17 2008-01-24 Francis Ka-Ming Chan Modulation of Programmed Necrosis
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
JP5134248B2 (ja) 2004-02-19 2013-01-30 バイエル・ファルマ・アクチェンゲゼルシャフト ジヒドロピリジノン誘導体
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
GB0410379D0 (en) 2004-05-11 2004-06-16 Univ Leicester Treatment of cancer
JP4703649B2 (ja) 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド 薬学的因子としてのピロール誘導体
US7595337B2 (en) 2005-02-10 2009-09-29 Merck & Co. Inc. Mitotic kinesin inhibitors
WO2006103995A1 (ja) 2005-03-25 2006-10-05 Kaneka Corporation 光学活性α－アミノ酸誘導体の製造方法
CA2620171A1 (en) 2005-08-25 2007-03-01 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
BRPI0617271A2 (pt) * 2005-10-11 2011-07-19 Intermune Inc inibidores de replicação viral
US7531671B2 (en) 2005-11-01 2009-05-12 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
US8324262B2 (en) 2005-12-20 2012-12-04 The Brigham And Women's Hospital, Inc. Tricyclic necrostatin compounds
AR056882A1 (es) 2006-02-01 2007-10-31 Bayer Cropscience Sa Derivados del fungicida n- cicloalquil- bencil- amida
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
CA2658223A1 (en) 2006-07-13 2008-01-17 4Sc Ag Benzopyranopyrazoles
JP5366812B2 (ja) 2006-10-10 2013-12-11 プレジデント アンド フェロウズ オブ ハーバード カレッジ 化合物、スクリーニング、および治療方法
WO2008148755A2 (en) * 2007-06-06 2008-12-11 Dsm Ip Assets B.V. Novel 5-substituted hydantoins
WO2009023272A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009100859A1 (en) 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Prediction of bone marrow toxicity
US20120061324A1 (en) * 2008-03-28 2012-03-15 Global Material Technologies, Inc. Element removal process and apparatus
US8304421B2 (en) 2008-09-30 2012-11-06 Vanderbilt University Indole compounds and their use as radiation sensitizing agents and chemotherapeutic agents
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
US20120122889A1 (en) 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
JP2010202575A (ja) 2009-03-03 2010-09-16 Takeda Chem Ind Ltd 複素環化合物
DE102009002044A1 (de) 2009-03-31 2010-10-07 Evonik Degussa Gmbh Dipeptide als Futtermitteladditive
JP5332882B2 (ja) 2009-04-30 2013-11-06 豊田合成株式会社 半導体発光素子
JP2010275229A (ja) 2009-05-28 2010-12-09 Ikutoku Gakuen ヒダントイン誘導体
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
AR080234A1 (es) 2010-02-25 2012-03-21 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo
AU2011227643A1 (en) 2010-03-16 2012-09-20 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011123609A1 (en) 2010-03-31 2011-10-06 Glaxo Group Limited Imidazolyl-imidazoles as kinase inhibitors
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2012061045A2 (en) 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
AU2012225506B2 (en) 2011-03-07 2016-11-17 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
EP2707714B1 (en) 2011-05-09 2019-10-09 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
CN102850252B (zh) 2011-06-30 2014-08-13 山东大学 一种3,5,5’-三取代乙内酰脲的制备方法
WO2013013826A1 (en) 2011-07-27 2013-01-31 Friedrich-Alexander-Universität Erlangen-Nürnberg Necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract
US9314328B2 (en) 2011-08-16 2016-04-19 W. L. Gore & Associates, Inc. Branched stent graft device and deployment
US20140221207A1 (en) 2011-08-27 2014-08-07 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom- formulations and uses
WO2013059791A2 (en) * 2011-10-21 2013-04-25 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
SG11201406837TA (en) 2012-05-04 2014-11-27 Novartis Ag Biomarkers for iap inhibitor therapy
US20150202250A1 (en) 2012-06-26 2015-07-23 Biovalence Sdn. Bhd. Anticancer treatment
WO2014008167A2 (en) 2012-07-02 2014-01-09 Cell Assay Innovations, Inc. Cell-based assays for post-translational enzyme activity
JPWO2014126127A1 (ja) 2013-02-13 2017-02-02 国立大学法人北海道大学 ネクロプトーシス関連疾患の治療用医薬組成物及びその有効成分のスクリーニング方法
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
CN105593373A (zh) 2013-02-27 2016-05-18 博德研究所 T细胞平衡基因表达、物质组合物及其使用方法
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
WO2014152182A1 (en) 2013-03-15 2014-09-25 President And Fellows Of Harvard College Deuterated heterocyclic inhibitors of necroptosis
EP2976331B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of hydantoin containing peptide products
US20160051629A1 (en) 2013-04-15 2016-02-25 Yeda Research And Development Co. Ltd. Inhibition of rip kinases for treating lysosomal storage diseases
GB201316651D0 (en) 2013-09-19 2013-11-06 Univ Southampton Asthma
WO2015039705A1 (en) 2013-09-23 2015-03-26 Carl Zeiss Smt Gmbh Multilayer mirror
EP2857839A1 (en) 2013-10-01 2015-04-08 AIT Austrian Institute of Technology GmbH Breast cancer diagnostic method and means
WO2015077709A2 (en) 2013-11-22 2015-05-28 World Biotechnology LLC Method for harvesting organic compounds from genetically modified organisms
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
WO2015105938A1 (en) 2014-01-08 2015-07-16 World Biotechnology LLC Genetically modified organisms to produce organic compounds
WO2015154197A1 (en) 2014-04-11 2015-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
EP3180014A1 (en) 2014-08-13 2017-06-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Prevention of tumour metastasis by inhibition of necroptosis
WO2016025129A1 (en) 2014-08-14 2016-02-18 Alhamadsheh Mamoun M Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
WO2016044777A1 (en) 2014-09-18 2016-03-24 Abbvie Inc. Hat inhibitors and methods for their use
EP3017825A1 (en) 2014-11-06 2016-05-11 Ludwig-Maximilians-Universität München An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same
EA201791289A1 (ru) 2014-12-11 2017-12-29 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы клеточного некроза и связанные с ними способы
KR102606064B1 (ko) 2014-12-24 2023-11-27 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 괴사 억제제
CA2972294C (en) 2014-12-24 2018-09-25 National Institute Of Biological Sciences, Beijing Necrosis inhibitors

Also Published As

Publication number Publication date
AU2015360291A1 (en) 2017-07-13
CN107530350A (zh) 2018-01-02
US9499521B2 (en) 2016-11-22
US20190023690A1 (en) 2019-01-24
IL252827A0 (en) 2017-08-31
KR20170123607A (ko) 2017-11-08
WO2016094846A1 (en) 2016-06-16
EP3229807A4 (en) 2018-10-17
CA2970525A1 (en) 2016-06-16
US20160304498A1 (en) 2016-10-20
AR102981A1 (es) 2017-04-05
US20160168128A1 (en) 2016-06-16
EP3229807A1 (en) 2017-10-18
SG11201704764PA (en) 2017-07-28
JP2017538712A (ja) 2017-12-28
EA201791289A1 (ru) 2017-12-29
US9944628B2 (en) 2018-04-17
US10508102B2 (en) 2019-12-17
TW201632516A (zh) 2016-09-16

Similar Documents

Publication Publication Date Title
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
MY196749A (en) Eif4a-inhibiting compounds and methods related thereto
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA033689B9 (ru) Ингибиторы g12c kras
MY176235A (en) Compounds that inhibit mcl-1 protein
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
ZA201606320B (en) Human plasma kallikrein inhibitors
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2015017964A (es) Inhibidores de bromodominio.
UA111382C2 (uk) Інгібітори протеїнкінази
MX378435B (es) Administración específica del sitio de un inhibidor de btk.
PH12019501639A1 (en) Jaki selective inhibitors
CA2983481A1 (en) Janus kinase inhibitor
PH12013501574A1 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PH12013501591A1 (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
PH12016501462A1 (en) Neprilysin inhibitors
WO2018125880A8 (en) Nrf2 activator
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam